8-K: Biofrontera Inc. Announces FDA Filing Acceptance for Increased Ameluz Dosage

Biofrontera Inc. has received FDA confirmation that its application to increase the maximum dosage of Ameluz from one to three tubes per treatment is complete and will proceed to substantive review.

Summary

• Biofrontera Inc. announced that the FDA has completed its filing review of the supplemental New Drug Application (sNDA) for Ameluz.
• The sNDA seeks to increase the maximum approved dosage of Ameluz from one to three tubes per treatment.
• The FDA has determined the application is sufficiently complete to permit a substantive review.
• The application is supported by two Phase 1 safety studies that showed the use of three tubes of Ameluz has similar safety parameters to one tube.
• The target action date for the FDA review is October 4, 2024.
• Approximately 13 million treatments are given each year for actinic keratosis (AK) in the US.

Sentiment

Score: 7

Explanation: The document is positive due to the FDA acceptance of the sNDA and the safety data. However, there are risks associated with regulatory approval and market adoption.

Positives

• The FDA's acceptance of the sNDA is a positive step towards potentially expanding the label for Ameluz.
• The safety studies indicate that using three tubes of Ameluz is as safe as using one tube.
• Increasing the dosage could make treatment more convenient for patients and more efficient for dermatologists.
• The potential approval could lead to increased use of Ameluz in the US.

Risks

• The FDA may not approve the sNDA, which would prevent the increase in dosage.
• The company's future success depends on the ability of its licensors to fulfill their obligations.
• The company faces risks related to supply chain disruptions, healthcare provider practices, and clinical trial outcomes.
• The company's ability to achieve and sustain profitability is not guaranteed.

Future Outlook

The company anticipates that the potential approval of the increased dosage will lead to increased use of Ameluz in the US. The company also notes that the clinical development strategy for Ameluz and the potential to expand its label are ongoing.

Management Comments

• Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera Inc., stated that the studies supporting the application showed robust safety parameters for the simultaneous use of three tubes.
• Hermann Luebbert believes that the approval, if granted, will lead to increased use of Ameluz in the US.

Industry Context

This announcement is relevant to the dermatology market, specifically for treatments of actinic keratosis. The potential increase in dosage could give Biofrontera a competitive advantage by offering a more convenient and efficient treatment option.

Comparison to Industry Standards

• The document does not provide specific comparisons to other companies or projects.
• However, the mention of 13 million treatments annually for AK in the US provides a benchmark for the potential market size.
• The safety data presented is consistent with industry standards for clinical trials.

Stakeholder Impact

• Shareholders may view this as a positive development, potentially increasing the value of the company.
• Dermatologists may find the increased dosage more efficient for treating patients.
• Patients may benefit from a more convenient treatment option.

Next Steps

• The FDA will conduct a substantive review of the sNDA.
• The company awaits the FDA's decision on the sNDA, with a target action date of October 4, 2024.

Key Dates

Keywords

Ameluz, FDA, sNDA, Actinic Keratosis, Photodynamic Therapy, Dermatology, Biofrontera, Dosage, Clinical Trials, BFRI